XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Condensed Consolidated Balance Sheets - USD ($)
Mar. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 19,601,829 $ 14,310,862
Short-term investments 86,013,044 130,982,913
Accounts receivable from affiliated entities 2,551,082 2,405,228
Prepaid expenses and other current assets 3,517,081 5,393,665
Prepaid expenses and other current assets from affiliated entities 0 20,432
Total current assets 111,683,036 153,113,100
Fixed assets, net 5,015,067 4,960,986
Investment in affiliated entity 2,654,269 2,780,287
Operating lease right-of-use assets 9,156,478 9,491,735
Other assets 605,315 605,315
Total assets 129,114,165 170,951,423
Current liabilities:    
Accrued clinical trial expenses 3,022,486 2,365,382
Operating lease liability 2,155,540 2,406,522
Grant funding liability 0 87,489
Grant funding liability from affiliated entity 21,918 21,918
Convertible senior notes 0 16,770,654
Total current liabilities 23,400,945 42,570,228
Operating lease liability, net of current portion 11,271,257 11,032,066
Total liabilities 34,672,202 53,602,294
Stockholders’ equity:    
Preferred stock 0 0
Common stock 23,370 22,792
Additional paid-in capital 1,748,529,814 1,740,954,074
Accumulated deficit (1,653,435,007) (1,622,965,136)
Accumulated other comprehensive loss (676,214) (662,601)
Total Inovio Pharmaceuticals, Inc. stockholders’ equity 94,441,963 117,349,129
Total liabilities and stockholders’ equity 129,114,165 170,951,423
Nonrelated Party    
Current liabilities:    
Accounts payable and accrued expenses 16,675,922 19,847,744
Related Party    
Current liabilities:    
Accounts payable and accrued expenses $ 1,525,079 $ 1,070,519